ARDELYX, INC. (NASDAQ:ARDX) Files An 8-K Regulation FD Disclosure

ME Staff 8-k
-
0
ARDELYX, INC. (NASDAQ:ARDX) Files An 8-K Regulation FD Disclosure

ARDELYX, INC. (NASDAQ:ARDX) Files An 8-K Regulation FD Disclosure
Item 7.01

Attached hereto as Exhibit 99.1 is a corporate presentation of Ardelyx, Inc. (the “Company”) incorporated by reference herein.

The information furnished under this Item 7.01 shall not be considered “filed” under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.

(d) Exhibits.

99.1    Presentation of Ardelyx, Inc.


ARDELYX, INC. Exhibit
EX-99.1 2 d835395dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Ardelyx,…
To view the full exhibit click here

About ARDELYX, INC. (NASDAQ:ARDX)

Ardelyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of minimally systemic therapeutic drugs that work in the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. The Company operates through research, development and commercialization of biopharmaceutical products segment. It has discovered and designed its lead product candidate, tenapanor, which is a minimally systemic small molecule that acts locally in the GI tract to inhibit the sodium transporter sodium-hydrogen exchanger 3 (NHE3) and reduce sodium and phosphorus uptake from the gut. It is evaluating tenapanor in over two pivotal Phase III clinical studies in patients with constipation-predominant irritable bowel syndrome (IBS-C). It is developing RDX022 for the treatment of hyperkalemia. RDX022 is its oral, non-absorbed potassium-binder. Its development programs also include RDX009 Program, RDX013 Program and RDX011 Program.